Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2016
NICE rejects United Therapeutics’ cancer drug
15 July 2016 - NICE has rejected United Therapeutics’ Unituxin (dinutuximab) in combination therapy to treat a rare cancer affecting children ...
Posted by Michael Wonder on 12 Jul 2016
Degarelix acetate: the prostate cancer lifeline drug finally approved after three-year wait
12 July 2016 - Thousands of men suffering from advanced prostate cancer have been thrown a lifeline after a drug that ...
Posted by Michael Wonder on 12 Jul 2016
NICE draft guidance extends treatment options for thousands of people with severe rheumatoid arthritis
12 July 2016 - New draft guidance from NICE means thousands of people suffering with severe rheumatoid arthritis will have more ...
Posted by Michael Wonder on 08 Jul 2016
NHS England, PTC reach agreement on Duchenne drug
8 July 2016 - Children in England suffering from a rare form of muscular dystrophy will soon be able to access ...
Posted by Michael Wonder on 07 Jul 2016
NICE approves first drug from old Cancer Drugs Fund
7 July 2016 - Dozens of patients with leukaemia will now have an automatic right to the drug bosutinib rather than ...
Posted by Michael Wonder on 06 Jul 2016
Charity calls on NICE to reverse Opdivo rejection
6 July 2016 - Kidney Cancer UK is calling on the National Institute for Health and Care Excellence to reverse a ...
Posted by Michael Wonder on 05 Jul 2016
UK cost agency rejects Bristol's Opdivo for kidney cancer
5 July 2016 - Bristol-Myers Squibb's immunotherapy drug Opdivo is not worth using on the state health service for treating kidney ...
Posted by Michael Wonder on 04 Jul 2016
NICE backs Ferring’s Firmagon
4 July 2016 - Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring's Firmagon ...
Posted by Michael Wonder on 24 Jun 2016
NICE publishes appraisal consultation for osimertinib mesylate (Tagrisso) for patients with non-small-cell lung cancer
24 June 2016 - NICE has published an appraisal consultation for AstraZeneca's Tagrisso. ...
Posted by Michael Wonder on 23 Jun 2016
New guidance from NICE recommends Humira (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition
22 June 2016 - AbbVie today announced that the NICE has published single technology appraisal guidance for the only licensed ...
Posted by Michael Wonder on 22 Jun 2016
NICE gives conditional backing for GSK’s Benlysta in lupus
22 June 2016 - NICE has today published final guidance which recommends UK pharma major GlaxoSmithKline’s Benlysta (belimumab) for treating systemic ...
Posted by Michael Wonder on 22 Jun 2016
UK drugs watchdog NICE approves five new treatments in coup for big pharma
22 June 2016 - The UK agency in charge of deciding which drugs the NHS will pay for has approved five ...
Posted by Michael Wonder on 18 Jun 2016
Drug combination for treating skin cancer approved for NHS use
17 June 2016 - Medicines regulator NICE moves at record speed to approve nivolumab for use with ipilimumab in melanoma patients. ...
Posted by Michael Wonder on 16 Jun 2016
NICE publishes appraisal consultation for cobimetinib hemifumarate (Cotellic) for patients with malignant melanoma
16 June 2016 - NICE has published an appraisal consultation for Roche's cobimetinib hemifumarate (Cotellic). ...
Posted by Michael Wonder on 16 Jun 2016
Updated NICE quality standard identifies areas for breast cancer improvement
15 June 2016 - NICE’s latest quality standard published today says people who have been diagnosed with a type of early ...